Your session is about to expire
← Back to Search
Monoclonal Antibodies
AZD0292 for Healthy Participants
Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from dosing (day 1) to end of the study (up to 13 weeks)
Summary
This trial will test how safe and well-tolerated a new drug, AZD0292, is when given in increasing amounts through a vein to healthy adults. It will also look at how the
Who is the study for?
This trial is for healthy adults who can participate in a study to test the safety of a new drug. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and have no conflicting conditions.
What is being tested?
The trial is testing AZD0292, given through an IV at increasing doses, against a placebo to see how safe it is and how the body processes it. Participants will be randomly assigned to receive either the drug or placebo.
What are the potential side effects?
Since this is an early-stage trial for AZD0292, potential side effects are being investigated. Common side effects for new drugs may include reactions at the injection site, nausea, headache, or fatigue.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from dosing (day 1) to end of the study (up to 13 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from dosing (day 1) to end of the study (up to 13 weeks)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with Adverse Events
Number of Participants with Adverse Events of Special Interest (AESI)
Secondary study objectives
Area Under Concentration-Curve from Time Zero to the Last Quantifiable Concentration (AUClast)
Area Under Concentration-Time Curve from Time Zero to Infinity (AUCinfinity)
Maximum Observed Drug Concentration (Cmax)
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: AZD0292 Dose 3Experimental Treatment1 Intervention
Participants will receive single dose of AZD0292 dose 3 as IV infusion on Day 1.
Group II: AZD0292 Dose 2Experimental Treatment1 Intervention
Participants will receive single dose of AZD0292 dose 2 as IV infusion on Day 1.
Group III: AZD0292 Dose 1Experimental Treatment1 Intervention
Participants will receive single dose of AZD0292 dose 1 as IV infusion on Day 1.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive matching placebo to AZD0292 as IV infusion on Day 1.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,427 Previous Clinical Trials
289,164,579 Total Patients Enrolled